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Stem cell research has been acclaimed to revolutionize thefuture of medicine, and to offer new treatments for previously
incurable diseases. Despite years of research, however, the
therapeutic potential of stem cell research has not yet been fully
realized. By June 2014, the US Food and Drug Administration had
approved only ﬁve stem cell-based medicinal products, all of which
cord blood derived hematopoietic stem cell products for the cure of
blood and immunological diseases. Anticipated treatments for
cancer, neurodegenerative disorders, gastroenterological, myocar-
dial, and other diseases are still far from routine applications. What
are the reasons for the slow progress in the stem cell ﬁeld, and the
mismatch between public expectations and actual achievements?
This article provides eight answers to these questions.
THE CREATION OF UNREALISTIC EXPECTATIONS
The derivation of the ﬁrst human embryonic stem cell lines in 1998,
and more recently the creation of iPS cells, have led to great
enthusiasm about the therapeutic potential of stem cells and a high
level of publicity. This enthusiasm has repeatedly turned into hype
and given rise to unrealistic expectations, in particular with regard to
the time at which new therapies will be available [Knowles, 2010].
These exaggerated expectations can be traced back to several causes:
The press trying to sell its products. Scientists who make inﬂated
claims in order to raise funding. Companies that are under pressure
to generate shareholder value. Politicians, because stem cells hold
the promise of scientiﬁc progress and economic proﬁt. And ﬁnally,
the patients and patient groups that correspond to these claims with
huge hopes, exerting pressure on scientists to move toward clinical
applications more rapidly [Wilson, 2009]. The overselling of the
promise and accessibility of stem cell treatments, however, stands in
sharp contrast with the regulatory, ﬁnancial, organizational, and
scientiﬁc challenges of the development of stem cell-based
therapeutic approaches.
REGULATORY STRINGENCY
Regulatory frameworks for the clinical application of stem cell
products are in most countries still evolving, often along with the
ﬁrst applications. In the USA, for instance, at the time Geron
Corporation ﬁled its investigational new drug application (IND) for
the world’s ﬁrst hESC-based medicinal product, the whitepapers for
the regulation of stem cell researchwere just generated. According to
Hans Keirstead, who had developed the product in collaborationwith
Geron, this emergent situation had resulted in signiﬁcant delays and
ﬁnancial losses for the company. Instead of setting out clear-cut
review criteria from the start, the FDA initiated a long-drawn-out
negotiation process that included the development of new assess-
ment parameters in the course of the application process. This
resulted not only in demands for additional preclinical studies, but at
one point also in a request to repeat an already completed preclinical
study along re-deﬁned regulatory speciﬁcations [Keirstead, 2012].
Regulatory requirements, as pointed out by Michael Rawlins, the
former chairman of the UK National Institute for Clinical Health and
Safety (NICE), have over the last few years become increasingly
stringent [Rawlins, 2010]. This is well reﬂected in the stem cell ﬁeld,
where the development of regulation was accompanied by public
controversies, scientiﬁc uncertainties, and fears of severe adverse
effects, such as undesired cell migration and tumorigenicity. The
high level of caution that underlies the regulation of stem cell-based
therapeutic approaches, at least in the context of the USA and
Europe, results also from fears of bad press, litigations, and nega-
tive public reactions, as happened after the death of 18-year-old
Jesse Gelsinger in 1999 in the gene therapy ﬁeld [Wilson, 2009]. But
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the slow speed of regulatory approval procedures is also caused by
organizational problemswithin drug regulatory agencies. According
to Andrew Eschenbach, the former commissioner of the US FDA, the
lack of ﬁnancial resources, and a shortage of adequately trained staff
within the FDA has stalled the realization of stem cell-based clinical
applications and other breakthrough technologies [Gaffney, 2012].
HIGH COSTS, LIMITED FUNDING
The increase of regulatory requirements comes along with added
costs. In average, the duration of the development of a newmedicine
from initial preclinical research to market approval is now 10 years,
and costs 1.2 billion US dollars [Collier, 2009]. In case of the Geron
trial, the preclinical development of its hESC program cost about 200
million US dollar, and was carried out over nearly a decade
[Keirstead, 2012]. As stated by Edward Wirth, the former chief
scientist of the hESC program at Geron, to test biodistribution,
dosing, delivery, toxicity, tumorigenicity, and immune rejection the
company conducted 24 preclinical studies before an IND application
could be ﬁled at the FDA in March 2008. These studies included in
total 1,977 rodents. The IND application that the corporation
submitted was 21,000 pages long, with more than 90% consisting of
data from the preclinical studies. According to Wirth, this was the
longest application the FDA had received at that time [Wirth, 2010].
After submission the FDA put the IND on a halt two times, for six and
13 months respectively, with the request to carry out additional
preclinical studies. For academic investigators and small-to-mid-
size companies these high costs are difﬁcult to bear, and carry the
risk of ﬁnancial unsustainability. Geron Corporation, for instance,
had to halt its ﬁrst hESC trial for ﬁnancial reasons in 2011, only
months after obtaining regulatory clearance by the FDA [Brennan,
2011].
Clinical stem cell research takes place in a highly challenging
funding environment. In high-income countries such as the USA,
Japan, Hong Kong, Singapore, and many European societies, the
obligatory conduct of Phase I to III clinical trials and subsequent
product release costs sum up to hundreds of millions of US dollars. A
large part of these expenses is usually covered by the pharmaceutical
industry, and sometimes through venture capital. In the stem cell
area, however, the industry has hesitated to invest for many years,
with companies waiting for further demonstrations of success and
potential applications [Doudement and Uppal, 2014]. Moreover, in
the aftermath of the ﬁnancial crisis, the venture capital ﬁeld was
turned on its head. The slow pace of stem cell research, and the
uncertain prospect of ﬁnancial returns are too risky for most venture
capitalists to invest [Keirstead, 2012]. Public funding is highly
limited. While money from public sources is available, it is usually
insufﬁcient to cover the long path from preclinical development to
the market, without assistance from the private sector or charitable
organizations. At present, the clinical research of many start-up
biotech companies and academia-initiated clinical infrastructures in
the stem cell ﬁeld is funded primarily through charitable
organizations, and the donations of high net worth individuals
(ibid). In sum, safety and scientiﬁc rigor come at a price. The
imposing of greater regulatory demands on investigators and
companies poses new challenges to attract funding, and delimits
chances for clinical translation and marketization.
THE HIGH FAILURE RATE OF CLINICAL TRIALS
Another reason that accounts for the slow progress rate of stem cell
researchis thehighfailurerateofclinical trials.Between2003and2011
only 10.4 percent of all candidate products that the FDAhad approved
for Phase I clinical trials were admitted to themarket [Hay et al., 2014].
Most of the product failures in Phase I to III trials are because the safety
andefﬁcacyofa testedproduct cannotbe reliablyproven.But thereare
other reasons too. These range from the inability to mobilize adequate
funding, toﬂaws in the clinical trial design, and failures in clinical trial
management [Ledford, 2011]. In addition to the premature ending of
the Geron trial, various failures of stem cell trial have been reported in
recent years. In 2012, for instance, a phase II trial of the US biotech
company Osiris for type I diabetes produced disappointing results
[Bersenev, 2012]. In earlier trials, the company’s stem cell product
Prochymal was also proven to be ineffective in clinical trials for graft-
versus-host-disease, Crohn’s disease, heart attack, and knee cartilage
repair [Feuerstein 2012]. Alexey Bersenev, a stem cell researcher from
theUniversity of Pennsylvania, has reported of failed stemcell trials in
2013 in ﬁve medical areas: cardiac repair, chronic ischemic cardio-
myopathy, diabetes, stroke, and critical limb ischemia [Bersenev,
2013]. These failures are a reminder that much of the therapeutic
potentialof stemcell therapies thatwas reported in thepress,wasbased
on promissory expectations, and not on hard clinical evidence.
THE CHALLENGE OF PATIENT RECRUITMENT
Another factor that accounts for delays or discontinuation of clinical
trials is the inability to recruit sufﬁcient numbers of patients. In the
USA, for instance, 80% of clinical trials fail to meet their initial
enrolment goal [Earls, 2012]. This challenge is also reﬂected in the
stem cell ﬁeld. In the Geron hESC trial, for example, it took 18
months to enroll ﬁve patients, over multiple study sites in the USA
[Keirstead, 2012]. The China Spinal Cord Injury Network, a
transcontinental research organization that is active in Hong
Kong, mainland China, Taiwan and the USA, encountered similar
problems. A Phase I/II study for chronic spinal cord injury with
umbilical cord blood mononuclear cells could not be completed in
Hong Kong, due to the inability to recruit sufﬁcient patients. The
studywas then conducted inmainland China, where recruitment was
fast and more easy [Rosemann, 2013]. Wise Young, the Network’s
director mentioned, in this respect, that the lack of volunteers is a
severe problem for stem cell research, especially for diseases with a
relatively low prevalence rate such as spinal cord injury. According
to Young, the only chance to overcome this problem is the creation of
multi-sited clinical studies in multiple countries [Young, 2012].1
1Blog contribution of Wise Young on CareCure, January 21, 2012. URL:
http://sci.rutgers.edu/forum/showthread.php?p=1480260 (lastaccessedAugust
26, 2012).
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THE NEED TO BUILD NEW CLINICAL
INFRASTRUCTURES
The absence of established clinical trials infrastructures is another
factor that has delayed progress in stem cell research. In more
established ﬁelds of medicine well functioning research platforms
have emerged over decades; these allow for effective and rapid forms
of clinical testing [Keating and Cambrosio, 2012]. In the stem cell
ﬁeld, however, the development of clinical infrastructures is often
still in initial stages. New alliances between researchers, hospitals,
universities, corporations and government institutions have to be
formed, and uniﬁed coordination structures must be established.
These processes are complicated by regulatory demands for good
manufacturing practice (GMP) labs and the development of
specialized surgical and injection procedures, which requires
cooperation between experts from highly divergent disciplines
and backgrounds. The formation of such standardized multi-center
clinical trial infrastructures is time and labor intensive, and involves
signiﬁcant costs. Moreover, it includes tasks and responsibilities for
which medical researchers are not trained, and that can only be
learned through experience [Keirstead, 2008]. A substantial amount
of energy is necessary to build such infrastructures, long before
actual clinical research can be conducted.
REGULATORY DIVERSITY ACROSS COUNTRIES
In contrast to established ﬁelds of drug research, that involve the
clinical testing of compounds and small molecules, no internation-
ally binding standards or harmonized regulatory framework are yet
in place for clinical stem cell interventions. Widely divergent
regulatory conditions exist across countries. This diverse regulatory
situation necessitates far-reaching forms of scientiﬁc self-gover-
nance and capacity building. The goal is to create compliance with
the demands of drug regulatory authorities in multiple countries.
These efforts involve changes of clinical research practices, inter-
institutional standardization, and the implementation of an effective
control and monitoring structure, so as to safeguard standardized
execution of research protocols. For academic research networks or
small-to-mid size biotech companies these tasks can be an important
obstacle. They require long-drawn-out periods of time, and addi-
tional costs. In countries where regulations for clinical stem cell
research are currently still emerging, such as in China or India,
delays may also be caused through unclear regulatory procedures, or
even the temporary refusal to accept new IND applications. In the
context of a regulatory reform that was initiated by the China Food
and Drug Administration [CFDA, 2012] in 2012, for example, the
agency refused incoming IND applications for stem cell-based
medicinal approaches for a period of several months. In this period,
researchers had either to wait, or to conduct their trials in another
country.
PUBLIC CONTROVERSIES
The impact of public controversies is another factor that has slowed
developments in stem cell medicine. It is now widely acknowledged,
that the ban on federal funding for hESC research during George
Bush’s term as President in the United States, has stiﬂed the stem cell
ﬁeld in the USA. The ban, which was linked to public discontent on
the use of human embryos, had not only resulted in restrictions of
public funding, but also in reservations to invest in the private sector
[Arrow, 2008]. But public concerns have also been expressed with
regard to the safety of clinical stem cell interventions. In 2009, for
example, PLOS Medicine reported of a 9-year-old boy with ataxia
telangiectasia who was treated with human fetal neural stem cells in
a hospital in Moscow. Four years after the ﬁrst treatment, the boy
was diagnosed with a multifocal brain tumor. Researchers showed,
that the tumor was of non-host origin; derived from the transplanted
neural stem cells [Amariglio et al., 2009]. On July 8, 2014 the new
scientist disclosed the case of a woman who received an autologous
tissue transplant containing olfactory ensheathing cells in the context
of a clinical trial in Portugal in 2006. These cells were implanted in the
patient’s spine, in the hope of repair of nerve damage. In 2013, due to
worsening pain, the woman underwent spinal surgery again. ‘The
surgeons removed a 3-cm-longgrowth,whichwas found to bemainly
nasal tissue, as well as bits of bone and tiny nerve branches that had
not connectedwith the spinal nerves’ [Wilson, 2014]. Even though the
removed tumor was not cancerous, such headlines reinforce public
concerns with stem cell research, and give rise to more prudent forms
of regulations. These reports of severe adverse effects may,
furthermore, increase reservations among patients to take part in
stem cell-based trials, and have a constraining effect on public
funding, private investments and stock prices.
CONCLUSIONS
The ﬁeld of stem cell research has been characterized by remarkable
developments in recent years. Stem cells are now used for the
modeling of diseases, and provide an increasing understanding of
disease mechanisms. Also, there has been ongoing progress in the
development of new treatments, which is epitomized by the launch
of the ﬁrst iPS trial in Japan this year, by market approval of ﬁrst
stem cell products and by a growing number of stem cell trials
worldwide. All in all, though, the realization of the therapeutic
potential of stem cell research has been slower than expected, and
slower than the promissory rhetoric of the media make the public
believe. This article has provided eight reasons that account for the
mismatch between public expectations and actual achievements. It
has become clear that the translation of stem cells into therapeutic
applications has been slowed down by several roadblocks. These
range from high costs, to stringent regulation, to a shortage of
funding, to the impact of public controversies, scientiﬁc challenges,
the need to build new clinical infrastructures, and the challenge of
navigating between different regulatory systems. With the reluc-
tance of the industry to invest into the stem cell ﬁeld, moreover, the
gap between academia and industry has widened. While academic
researchers have made outstanding achievements, these experts are
usually not in the position to translate these inventions into the
clinic independently. The investment risks for small-to-mid size
biotech companies moreover are high, and the resources of these
corporations are limited. Another issue is that, at a global level,
access to the ﬁnancial and infrastructural resources that are required
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for the conduct of rigorous Phase I to III trials is highly stratiﬁed, and
usually restricted to a small group of elite scientists. For many
physicians and scientists that are involved in stem cell research,
access to these resources remains out of reach [Sleeboom-Faulkner
and Patra, 2011]. This is true for many researchers in high-income
countries, but even more so for researchers in low-to-mid income
countries. Against this background, it is not surprising that scientists
and clinicians that do not have access to these resources seek for
alternatives. In countries with ﬂexible regulations, or the existence of
regulatory loopholes, researchers have increasingly translated stem
cell-based approaches outside of the clinical trial format, and exterior
to the review of drug regulatory authorities [Sipp 2009]. Professional
organizations, such as the International Cellular Medicine Society
(ICMS),which consists largelyof researchers involved in experimental
for-proﬁt interventions, have developed alternative guidelines and
standards, as well as institutional accreditation procedures that
operate independently of drug regulatory agencies (Rosemann, under
review). A global landscape of unproven experimental for proﬁt
applications with stem cells has emerged. Whether the therapeutic
promise of stem cell research can be realized in this way is of course
highly questionable. Due to the conﬂict of interest between commer-
cial and medical interests among experimental for proﬁt providers of
stem cell applications, the absence of systematic methodological
protocols, and the lack of reliable forms of peer-review, claims
regarding therapeutic efﬁcacy and safety can hardly be veriﬁed, and
more rigorous forms of clinical testing will be indispensable.
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